Bristol Myers Squibb (BMY) Stock Price, Fundamentals & Analysis

What BMY does

Bristol Myers Squibb (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its portfolio includes treatments such as Opdivo for anti-cancer indications, Orencia for active rheumatoid arthritis and psoriatic arthritis, Yervoy for the treatment of unresectable or metastatic melanoma, Reblozyl to treat anemia, Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma, Opdualag to treat unresectable or metastatic melanoma, Camzyos for the treatment of symptomatic obstructive HCM, Zeposia to treat relapsing forms of multiple sclerosis, Abecma for the treatment of patients with relapsed or refractory multiple myeloma, Sotyktu to treat moderate-to-severe plaque psoriasis, Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), and Cobenfy to treat schizophrenia. Bristol Myers Squibb is part of the S&P 500 and operates in the Healthcare sector alongside peers such as Becton Dickinson (BDX), Vertex Pharmaceuticals (VRTX), and Solventum (SOLV).

Key numbers explained

• 61.15 USD is the current share price, representing the cost to buy one share in the market.
• 124.91B USD is the market capitalization, the total value of all outstanding shares.
• The trailing P/E ratio of 13.5 shows how much investors pay per dollar of the company's last 12 months of earnings.
• The forward P/E ratio of 9.3 uses expected future earnings and is often read as a measure of how the market values growth prospects.
• 4.54 USD is the trailing 12-month earnings per share, the portion of profit allocated to each share.
• The dividend yield of 4.05% indicates the annual dividend payment as a percentage of the current share price.
• The ex-dividend date is Oct 2, 2026, the date by which you must own the share to receive the next dividend payment.
• 55% of earnings is paid out as dividends, showing the share of profit returned to shareholders.
• 0.23 is the beta, a measure of the stock's volatility compared to the overall market.
• 41% is the price change over the last 52 weeks, showing the total return from one year ago to today.

Recent news

Recent headlines include a music festival raising over $3.6M to build a more connected future of mental health, an article questioning what AbbVie is no longer telling investors, and another exploring the best case for Pfizer stock. Additional coverage notes that Bristol Myers Squibb has joined RAAP as its newest member, and articles highlight how to maximize a retirement portfolio with top-ranked dividend stocks and four elite dividend stocks yielding up to 6.14% with diversified pipelines.

What to watch

Investors typically monitor the pipeline of new drug approvals and clinical trial results, as these can affect future revenue. Regulatory decisions, patent expirations, and pricing pressures in the healthcare sector are also relevant factors. The company's debt-to-equity ratio of 201.9% and its operating margin of 34.4% are structural elements that can influence how the business responds to economic cycles. For broader context, investors may compare BMY with other healthcare names such as Incyte (INCY) or CVS Health (CVS).